Transcranial Doppler Screening in a Current Cohort of Children With Sickle Cell Anemia: Results From the DISPLACE Study
- PMID: 33625093
- PMCID: PMC8481351
- DOI: 10.1097/MPH.0000000000002103
Transcranial Doppler Screening in a Current Cohort of Children With Sickle Cell Anemia: Results From the DISPLACE Study
Abstract
Stroke prevention guidelines for sickle cell anemia (SCA) recommend transcranial Doppler (TCD) screening to identify children at stroke risk; however, TCD screening implementation remains poor. This report describes results from Part 1 of the 28-site DISPLACE (Dissemination and Implementation of Stroke Prevention Looking at the Care Environment) study, a baseline assessment of TCD implementation rates. This report describes TCD implementation by consortium site characteristics; characteristics of TCDs completed; and TCD results based on age. The cohort included 5247 children with SCA, of whom 5116 were eligible for TCD implementation assessment for at least 1 study year. The majority of children were African American or Black, non-Hispanic and received Medicaid. Mean age at first recorded TCD was 5.9 and 10.5 years at study end. Observed TCD screening rates were unsatisfactory across geographic regions (mean 49.9%; range: 30.9% to 74.7%) independent of size, institution type, or previous stroke prevention trial participation. The abnormal TCD rate was 2.9%, with a median age of 6.3 years for first abnormal TCD result. Findings highlight real-world TCD screening practices and results from the largest SCA cohort to date. Data informed the part 3 implementation study for improving stroke screening and findings may inform clinical practice improvements.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Dr J.K. reports receiving grants (R01HL133896, U01HL133990) from the National Institutes of Health (NIH), the Health Resources and Services Administration and the Centers for Disease Control. She has served as a Principal Investigator on studies funded by Novartis Pharmaceuticals Corporation, Ironwood Therapeutics Inc., Imara Inc., Baxalta US Inc., Bluebird Bio Inc. She has received honoraria from Novartis Pharmaceuticals Corporation, MEDSCAPE, MD Magazine, Terumo and Bluebird Bio Inc. and travel support for Global Blood Therapeutics. Dr S.P. reports receiving a grant (K23NR017899) from NIH. Dr C.L.M. reports receiving grants (R01HL133896, U01HL133990) from the NIH. Dr R.J.A. reports receiving a grant (R01HL133896) from the NIH and the American Heart Association and consulting honoraria from Global Blood Therapeutics. The remaining authors declare no conflict of interest.
References
-
- Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11. - PubMed
-
- Adams RJ. Big strokes in small persons. Arch Neurol. 2007;64(11):1567–1574. - PubMed
-
- Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood. 1998;91(1):288 – 294. - PubMed
-
- Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109(3):526–535. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical